Research Progress in Pyroptosis, Drug Therapy and Immunotherapy in Glioblastoma
10.13748/j.cnki.issn1007-7693.20232189
- VernacularTitle:细胞焦亡与药物治疗及免疫治疗在胶质母细胞瘤中的研究进展
- Author:
Ke TANG
1
,
2
;
Ni HUANG
3
,
4
;
Qinyou TAN
3
,
4
,
5
Author Information
1. Teaching and Research Section of Clinical Pharmacy and Clinical Pharmacology, Affiliated H
2. School of Pharmacy, Guilin Medical College, Guilin 541001, Chinaospital of Guilin Medical College, Guilin 541001, China
3. Teaching and Research Section of Clinical Pharmacy and Clinical Pharmacology, Affiliated Hospital of Guilin Medical College, Guilin 541001, China
4. School of Pharmacy, Guilin Medical College, Guilin 541001, China
5. China US Health and Disease Lipid Research Center, Guilin 541001, China
- Publication Type:Journal Article
- Keywords:
pyroptosis;
glioblastoma;
immunotherapy;
tumor microenvironment
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(2):287-294
- CountryChina
- Language:Chinese
-
Abstract:
Pyroptosis, a form of inflammatory cell death mediated by the Gasdermins family, promotes the release of inflammatory mediators and activates immune cell populations such as NK cells, T cells and macrophages in the tumor microenvironment(TME) to exert immune-regulating and anti-tumor effects. Glioblastoma(GBM) is the most serious and malignant glioma, and the median survival of patients diagnosed with GBM is less than 2 years, and the presence of the blood-brain barrier makes it difficult to deliver drugs to the brain, thus affecting the effect of drugs against GBM. Therefore, it is important to explore new measures and mechanisms to treat GBM, which has a complex TME with a large number of immune cell populations that are often immunosuppressed by GBM. Cellular pyroptosis as a mode of cell death capable of activating immunity, has the effect of activating the body’s immunity to help reverse TME immunosuppression. This review will focus on the relationship between cell pyroptosis and the immune system, how cell pyroptosis affects the immune cell population of TME in GBM, and the new progress in drug research on cell pyroptosis pathways in GBM treatment, providing new directions and strategies for future clinical treatment of GBM.
